HARMONY BIOSCIENCES HOLDINGS, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.20% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. effective income tax rate reconciliation, other adjustments, percent for the quarter ending 2026-06-30 was -0.20%, a 133.33% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. effective income tax rate reconciliation, other adjustments, percent for the quarter ending 2025-09-30 was 0.60%, a 50.00% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. effective income tax rate reconciliation, other adjustments, percent for the quarter ending 2025-06-30 was 0.60%, a 0.00% change year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. effective income tax rate reconciliation, other adjustments, percent for the quarter ending 2025-03-31 was 0.20%, a 50.00% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was 0.50%.
- HARMONY BIOSCIENCES HOLDINGS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -0.90%, a 250.00% decline from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.60%.
- HARMONY BIOSCIENCES HOLDINGS, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -0.30%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 3 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 6 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 9 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -0.20% 10-Q · filed 2026-08-04 | -0.10% 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | 0.50% 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | 0.60% 10-Q · filed 2025-11-04 | 0.50% 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 0.60% 10-Q · filed 2026-08-04 | 0.40% 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | 0.20% 10-Q · filed 2026-05-07 | ||||
| 2024-12-31 | -0.90% 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | 0.40% 10-Q · filed 2025-11-04 | 0.40% 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | 0.60% 10-Q · filed 2025-08-05 | 0.30% 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | 0.40% 10-Q · filed 2025-05-06 | ||||
| 2023-12-31 | 0.60% 10-K · filed 2026-02-24 | 0.90% 10-K · filed 2024-02-22 | |||
| 2023-09-30 | 0.60% 10-Q · filed 2024-10-29 | 0.30% 10-Q · filed 2024-10-29 | |||
| 2023-06-30 | 0.60% 10-Q · filed 2024-08-06 | 0.40% 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | 0.40% 10-Q · filed 2024-04-30 | ||||
| 2022-12-31 | -0.30% 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | 0.70% 10-Q · filed 2023-10-31 | ||||
| 2021-12-31 | -0.20% 10-K · filed 2024-02-22 | ||||
| 2020-12-31 | -3.60% 10-K · filed 2023-02-21 | ||||
| 2019-12-31 | 0.40% 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |